Strong IP keeps collaboration alive, allowing companies to attract capital, strike partnerships, and bring innovations to patients, according to legal experts at Ice Miller.

Tom Wells at 4C Associates, explores the future of biologistics, or how the packaging, storage, and logistics for biologics ...

Leadership means knowing when to jump in and when to let someone else worry about the details, writes Hope Mueller, SVP of Corporate Development and Strategy at Currax Pharmaceuticals.

Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes ...

Part one of a two-part series on FDA Commissioner Martin Makary, M.D.s comments at the Gailen Forum in New York City on October 30, 2025.

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

In a complex global and competitive world, formulating a plan without testing it against likely external reactions is the equivalent of walking into a battlefield without the right weapons or a plan ...

Implementing AI in drug discovery offers significant potential for reducing operating costs, though the extent varies widely. A Deloitte report suggests AI could cut drug development costs by up to 70 ...

THERE ARE THREE ESSENTIAL COMPONENTS TO A WORKING VALUE-BASED CONTRACT: it must: 1) focus on real and meaningful patient outcomes to which payers and manufacturers can agree; 2) provide the payer with ...

In the 1980s, Lisa Conte was a biopharmaceutical venture capitalist. But she also was an aspiring entrepreneur, having a little business on the side called Wild Woods, which imported wood and ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...